These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31346151)

  • 1. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
    Baek SK; Lee KT; Bae SB; Lee SC
    Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalizing medicine for metastatic colorectal cancer: current developments.
    Marques AM; Turner A; de Mello RA
    World J Gastroenterol; 2014 Aug; 20(30):10425-31. PubMed ID: 25132758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future targets and therapies in metastatic colorectal cancer.
    Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
    J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
    Atreya CE; Yaeger R; Chu E
    Am Soc Clin Oncol Educ Book; 2017; 37():246-256. PubMed ID: 28561718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
    To KK; Tong CW; Wu M; Cho WC
    World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.
    Spiliopoulou P; Arkenau HT
    World J Gastroenterol; 2014 Aug; 20(30):10288-95. PubMed ID: 25132745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
    Davis LE
    Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer.
    Henry JT; Johnson B
    Chin Clin Oncol; 2019 Oct; 8(5):49. PubMed ID: 31500426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
    Stintzing S; Stremitzer S; Sebio A; Lenz HJ
    Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients.
    Puzzoni M; Ziranu P; Demurtas L; Lai E; Mariani S; Liscia N; Soro P; Pretta A; Impera V; Camera S; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Scartozzi M
    Future Oncol; 2020 Jan; 16(2):4337-4339. PubMed ID: 31793396
    [No Abstract]   [Full Text] [Related]  

  • 11. Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study.
    Smedman TM; Guren TK; Line PD; Dueland S
    Transpl Int; 2019 Nov; 32(11):1144-1150. PubMed ID: 31209941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
    Rebersek M
    Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist.
    Costi R; Leonardi F; Zanoni D; Violi V; Roncoroni L
    World J Gastroenterol; 2014 Jun; 20(24):7602-21. PubMed ID: 24976699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
    Hanna DL; Lenz HJ
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic colorectal cancer- third line therapy and beyond.
    Foo T; Roy A; Karapetis C; Townsend A; Price T
    Expert Rev Anticancer Ther; 2024 May; 24(5):219-227. PubMed ID: 38526540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
    Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
    World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
    Strickler JH; Wu C; Bekaii-Saab T
    Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.
    Rodrigues D; Longatto-Filho A; Martins SF
    Biomed Res Int; 2016; 2016():6896024. PubMed ID: 27563673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.